Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Conclusions: In patients with r/r aggressive B-NHL and predominantly progressive disease following ≥2 cycles of platinum-based S1 chemotherapy, blinatumomab monotherapy as S2 therapy induced CMR/PMR in 37% of patients and led to HSCT in 20%. When considering that 66% of the patients enrolled had progressive disease and that 47% received the therapeutic dose, blinatumomab showed promising efficacy consistent with the efficacy and safety demonstrated in earlier blinatumomab B-NHL trials and potentially offers a treatment option for patients unresponsive to standard salvage regimens.DisclosuresCoyle: Amgen Inc.: Other: non-financial relationship. Morley: Amgen Inc.: Honoraria, Other: non-financial; Roche: Honoraria, Other: non-financial, Research Funding. Rambaldi: Celgene: Consultancy; Roche: Consultancy; Omeros: Consultancy; Italfarmaco: Consultancy; Novartis: Consultancy; Amgen Inc.: Consultancy; Pfizer: Consultancy. Zhang: Amgen Inc.: Employment, Equity Ownership. Jung: Amgen Inc.: Employment, Equity Ownership. Franklin: Amgen Inc.: Employment, Equity Ownership.
Source: Blood - Category: Hematology Authors: Tags: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: New Agents Source Type: research